Analysts’ Top Healthcare Picks: Johnson & Johnson (JNJ), Legend Biotech (LEGN)
TipRanks (Fri, 26-Jun 8:20 AM ET)
Globe Newswire (Tue, 23-Jun 8:00 AM ET)
Legend Biotech Prices $226 Million ADS Offering to Bolster Cell Therapy Expansion
TipRanks (Mon, 22-Jun 5:17 PM ET)
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Seeking Alpha News (Mon, 22-Jun 9:32 AM ET)
Legend Biotech Corporation Announces Pricing of Public Offering
Globe Newswire (Wed, 17-Jun 9:21 PM ET)
Legend Biotech Corporation Announces Proposed Public Offering
Globe Newswire (Wed, 17-Jun 4:29 PM ET)
Globe Newswire (Sun, 14-Jun 3:15 AM ET)
Globe Newswire (Tue, 2-Jun 9:30 AM ET)
Globe Newswire (Mon, 1-Jun 10:00 AM ET)
Legend Biotech Spotlights Solid Tumor CAR-T Advances and Expanded Clinical Data at ASCO 2026
Market Chameleon (Fri, 22-May 3:06 AM ET)
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.
As of June 26, 2026, LEGN stock price climbed to $28.69 with 2,109,233 million shares trading.
LEGN has a beta of 1.10, meaning it tends to be more sensitive to market movements. LEGN has a correlation of 0.05 to the broad based SPY ETF.
LEGN has a market cap of $5.55 billion. This is considered a Mid Cap stock.
Last quarter Legend Biotech - American Depositary Shares reported $305 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.11.
In the last 3 years, LEGN traded as high as $77.32 and as low as $16.24.
The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, CANC, PBE, EEM.
LEGN has underperformed the market in the last year with a price return of -14.2% while the SPY ETF gained +21.3%. However, in the short term, LEGN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +63.0% vs +11.3% return in SPY. But in the last 2 weeks, LEGN shares have been beat by the market, returning -20.9% compared to an SPY return of -0.9%.
LEGN support price is $27.04 and resistance is $29.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.